[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, Zhang XL: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol; 2010 Apr 21;16(15):1901-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
  • AIM: To investigate the procedure, feasibility and effects of laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers.
  • METHODS: From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding.
  • Each patient underwent CHIPC three times after laparoscope-assisted perfusion catheters placing.
  • During the follow-up, 13 patients died 2-9 mo after CHIPC, with a median survival time of 5 mo.
  • Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment.
  • CONCLUSION: Laparoscope-assisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.
  • [MeSH-major] Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy / methods. Peritoneal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2003 Jul;83(3):147-53 [12827682.001]
  • [Cites] In Vivo. 2009 Jan-Feb;23(1):187-90 [19368148.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):358-61 [16112182.001]
  • [Cites] Suppl Tumori. 2005 May-Jun;4(3):S122-3 [16437944.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):1038-43 [16843875.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):682-5 [16631341.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):625-7 [16822641.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x [17606199.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3274-82 [17653591.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):339-44 [17943387.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):154-8 [17640844.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):542-6 [17929098.001]
  • [Cites] World J Gastroenterol. 2008 Feb 28;14(8):1159-66 [18300340.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2008 Aug;18(4):426-8 [18716551.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):540-3 [15922890.001]
  • (PMID = 20397270.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2856833
  • [Keywords] NOTNLM ; Chemotherapy / Gastric cancer / Intraperitoneal hyperthermic perfusion / Laparoscopy / Malignant ascites
  •  go-up   go-down


2. Ulusan S, Koç Z, Kayaselçuk F: Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. Turk J Gastroenterol; 2008 Jun;19(2):129-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
  • Our objective was to show the unusual imaging characteristics of cystic liver metastases from a malignant gastrointestinal stromal tumor before and after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Colon / pathology. Fatal Outcome. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / ultrasonography. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Liver / ultrasonography. Male. Neoplasm Invasiveness. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110671.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


3. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch; 2008 May;452(5):525-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.
  • To investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis, the clinicopathological characteristics of MT carcinomas were analyzed and compared with intestinal-type (IT) and diffuse-type (DT) carcinomas.
  • The expression of Ki-67, caspase-3, p53, fragile histine triad (FHIT), maspin, extracellular matrix metalloproteinase inducer (EMMPRIN), vascular growth factor (VEGF), MUC-2, 4, 5AC and 6, CD44, E-cadherin, beta-catenin, and phosphorylated glycogen synthase kinase 3beta-ser9 (P-GSK3beta-ser9) was examined on tissue microarrays using immunohistochemistry.
  • It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (p < 0.05).
  • All the markers except MUC-5AC showed higher expression in IT than DT carcinomas (p < 0.05).
  • The MT diffuse component displayed a higher expression of FHIT, VEGF, and P-GSK3beta-ser9 than DT carcinoma (p < 0.05).
  • The accumulative survival rate of the IT carcinoma patients was higher than the other types (p < 0.05).
  • The invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas (p < 0.05).
  • These findings suggested that MT carcinomas were also indicated to be more aggressive than IT and DT carcinomas.
  • Significant differences were observed in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between IT and DT carcinomas, whereas only a few of these characteristics showed differences between the MT intestinal and diffuse parts, thus suggesting that both the MT components might originate from the stem cells with similar genetic traits, but follow different histogenic pathways.
  • [MeSH-major] Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Adhesion. Cell Proliferation. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Protein Array Analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2353-60 [16821616.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):259-65 [17352241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] Br J Surg. 2000 May;87(5):618-26 [10792320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8 [11205493.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2527-40 [11749387.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1989 Jan;11(1):37-40 [2550197.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • (PMID = 18266006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329735
  •  go-up   go-down


Advertisement
4. Akita N, Maruta F, Seymour LW, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J, Miyagawa S: Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci; 2006 Oct;97(10):1075-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor-associated phages were amplified and the biopanning cycle was repeated five times to enrich for high affinity tumor-selective binding peptides.
  • In addition, the KLP phages were more likely to bind to cancer cells in malignant ascites derived from a patient with recurrent gastric cancer.
  • The peptide motif KLP seems a potential targeting ligand for the treatment of peritoneal metastasis of gastric cancer.
  • [MeSH-major] Oligopeptides / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Amino Acid Motifs. Amino Acid Sequence. Animals. Antibiotics, Antineoplastic / therapeutic use. Ascites / metabolism. Ascites / pathology. Cell Adhesion Molecules / chemistry. Cell Adhesion Molecules / metabolism. Consensus Sequence. Doxorubicin / therapeutic use. Female. Humans. Liposomes. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Peptide Library

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984380.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cell Adhesion Molecules; 0 / Liposomes; 0 / Oligopeptides; 0 / Peptide Library; 0 / kalinin; 0 / seryl-tryptophyl-lysyl-leucyl-prolyl-prolyl-serine; 80168379AG / Doxorubicin
  •  go-up   go-down


5. Tsushima T, Tsuji Y, Abe S, Tamura F, Mizushima T, Nagashima H, Oura K, Kukitsu T, Sumiyoshi T, Yoshizaki N, Kondo H: [A case of metastatic gastric endocrine cell carcinoma which could be curably resected after chemotherapy with S-1/CDDP]. Gan To Kagaku Ryoho; 2008 May;35(5):817-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic gastric endocrine cell carcinoma which could be curably resected after chemotherapy with S-1/CDDP].
  • Gastric endocrine cell carcinoma is known to be highly malignant with a poor prognosis, and no standard treatment has been established.
  • We experienced a case of endocrine cell carcinoma of the stomach with liver and lymph node metastases.
  • The lesions became resectable at curability B after chemotherapy with S-1/cisplatin (CDDP).
  • A 30-mm tumor was found at the greater curvature of the lower body of the stomach, and was histologically diagnosed as an endocrine cell carcinoma from the biopsy specimen.
  • A computed tomography (CT) scan and abdominal magnetic resonance imaging (MRI) showed masses at S5 and S6 of the liver, and No. 4 lymph node enlargement.
  • We started chemotherapy with a daily dose of S-1 administered on days 1 to 14 and CDDP of 70 mg/m(2) on day 8, every 4 weeks.
  • After three courses of treatment, the primary lesion became a small scar and the metastatic lesions vanished from the CT and MRI.
  • Then we performed distal gastrectomy with lymph node dissection and partial liver resectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Okumoto T, Tomiyama K, Ino H, Kanaya Y, Maruyama S, Otani J, Yokoyama N, Soda M: [A case of malignant lymphoma of the stomach in which preoperative chemotherapy provided a complete response]. Gan To Kagaku Ryoho; 2002 Jun;29(6):943-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma of the stomach in which preoperative chemotherapy provided a complete response].
  • We have encountered a case of malignant lymphoma of the stomach in which a complete remission was confirmed in a resected specimen after chemotherapy.
  • A biopsy from gastric endoscopy indicated malignant lymphoma of diffuse large B-cell type.
  • The patient was assumed to be inoperable due to enlargement of the tumor and lymph node metastasis, and THP-COP chemotherapy was carried out.
  • After four courses of the THP-COP regimen, endoscopic examination revealed a significant tumor reduction.
  • Total gastrectomy and splenectomy with lymph node dissection (D2) were performed after chemotherapy.
  • No tumor cells were detected in any sections of the specimen or regional lymph nodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / therapeutic use. Stomach Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Remission Induction. Splenectomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12090049.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


7. Koizumi Y, Hara A, Tomita M, Sakamoto K, Obata H, Shiomi T, Nakajo S, Hashimoto K: [A case of advanced gastric cancer attaining histological CR of paraaortic lymph node after TS-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1351-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer attaining histological CR of paraaortic lymph node after TS-1/CDDP neoadjuvant chemotherapy].
  • A 60-year-old male complaining of anemic symptoms went through examinations and was diagnosed with gastric cancer (cardia, type 3', cT2, cN3, cH0, cP0, cM0, cStage IV).
  • Poor prognosis was predicted, yet we tried neoadjuvant chemotherapy (NAC) expecting down staging of the tumor.
  • The tumor itself showed PR-MR to the chemotherapy, but all the lymph nodes were expected to attain PR from CT findings.
  • Macroscopically, the stomach seemed to be penetrated into serosa by the tumor, i.e., se invasion was suggested, yet histologically no cancerous cells were detected within mp and ss layer.
  • Definitely no malignant cells were detected throughout all the lymph node specimens (Grade 3).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518420.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Testroote M, Hoornweg M, Rhemrev S: Rectal GIST presenting as a submucosal calculus. Dig Dis Sci; 2007 Apr;52(4):1047-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report presents an incidental finding of a rectal GIST (gastrointestinal stromal tumor) presenting as a submucosal calculus, not previously reported.
  • X-ray photos, computerized tomography (CT)-scan and a magnetic resonance imaging (MRI) scan clearly showed a calculus.
  • Analysis showed it was a rectal GIST, a rare mesenchymal tumor of the gastrointestinal tract, which expressed CD117 (or c-kit, a marker of kit-receptor tyrosine kinase) and CD34.
  • In general, GISTs are rare mesenchymal tumors of the gastrointestinal tract (nerve tissue, smooth muscle).
  • The most important location is the stomach; the rectal location is rare.
  • Usually, the classic signs of malignancy such as cellular invasion and metastasis are missing.
  • A set of histologic criteria stratifies GIST for risk of malignant behavior such as mitotic activity and tumor size, cellular pleomorphism, developmental stage of the cell and quantity of cytoplasma [7,13].
  • Tumors with a high mitotic activity and size above 5 cm are considered malignant.
  • Recent pharmacological advances such as tyrosine kinase inhibitors have determined c-kit (i.e., CD117) as the most important marker, amongst others.
  • C-kit positive tumors respond extremely well to chemotherapy with Imatinib (Glivec, Gleevec) [10-12].
  • [MeSH-minor] Calcinosis / complications. Calcinosis / diagnosis. Calcinosis / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Ureteral Calculi / complications. Ureteral Calculi / diagnosis. Ureteral Calculi / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol. 2003;38(2):186-9 [12640535.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2051-5 [14606351.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):373-7 [15086741.001]
  • [Cites] Clin Radiol. 2004 Jun;59(6):487-98 [15145718.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] J Gastroenterol. 2000;35(10):779-83 [11063223.001]
  • [Cites] Eur Radiol. 2001;11(2):216-9 [11218017.001]
  • [Cites] Am Surg. 2001 Feb;67(2):135-7 [11243536.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Mar;13(3):283-6 [11293450.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • (PMID = 17268837.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1914226
  •  go-up   go-down


9. Kinoshita K, Kondo K, Watanabe K: [A case of advanced gastric cancer with distant lymph node metastases in cervical, supraclavicular and superior mediastinum successfully treated with S-1/Cisplatin (CDDP)/Lentinan combination chemotherapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):707-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with distant lymph node metastases in cervical, supraclavicular and superior mediastinum successfully treated with S-1/Cisplatin (CDDP)/Lentinan combination chemotherapy].
  • The patient was a 76-year-old Japanese woman suffering from a left cervical tumor.
  • An endoscopic examination revealed type 3 gastric cancer in the middle body of the stomach.
  • Histopathological study showed poorly-differentiated adenocarcinoma in both stomach and supraclavicular lymph node.
  • However, gastric endoscopic biopsy still showed a remnant malignant lesion.
  • After 5 courses of the chemotherapy, both the primary lesion and the distant lymph node swelling disappeared on gastroscopy and PET-CT, respectively, which was a so-called complete response(CR).
  • After that, only S-1 was administered for 3 weeks followed by a drug-free week as a course.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Head / pathology. Lentinan / therapeutic use. Neck / pathology. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Female. Gastroscopy. Humans. Lymphatic Metastasis. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414031.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Mizoshita T, Kataoka H, Kubota E, Shimura T, Mori Y, Wada T, Ogasawara N, Sasaki M, Kamiya T, Sakamoto M, Akamo Y, Joh T: An endocrine cell carcinoma with gastric-and-intestinal mixed phenotype adenocarcinoma component in the stomach. Dig Endosc; 2009 Oct;21(4):258-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An endocrine cell carcinoma with gastric-and-intestinal mixed phenotype adenocarcinoma component in the stomach.
  • A 77-year-old man complained of bodyweight loss, and a Borrmann 3 type lesion was observed endoscopically in the anterior wall of angular region of the stomach.
  • The patient underwent distal gastrectomy plus systemic lymph node (LN) dissection (D2 LN dissection), and pathological examination revealed ECC invading the subserosa, and no LN metastasis (pT2N0M0).
  • The lesion also contained a moderately differentiated type tubular adenocarcinoma component, which was judged to be gastric-and-intestinal mixed (GI type) phenotype, using gastric and intestinal exocrine cell markers.
  • The patient now (March 2008, about 19 months since the surgery) continues this chemotherapy with no recurrence.
  • In conclusion, we experienced ECC with a GI type adenocarcinoma component.
  • The ECC cases with the GI type adenocarcinoma component may have a relatively good prognosis, being similar to the results of advanced gastric cancers from the viewpoint of gastric and intestinal phenotypic expression.
  • [MeSH-major] Carcinoma / pathology. Endoscopy. Enteroendocrine Cells / pathology. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961526.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


11. Yang XJ, Li Y, Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol; 2010 May 1;101(6):457-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center.
  • BACKGROUND: This work was to evaluate cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (GC).
  • METHODS: CRS and HIPEC were performed on 28 GC patients with peritoneal carcinomatosis (PC) and/or malignant ascites, with survival and perioperative safety as study endpoints.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / complications. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Gastrectomy. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Quality of Life. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20401915.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy.
  • Neuroendocrine carcinoma of the stomach is an uncommon tumor, usually associated with highly malignant biological behavior and extremely poor prognosis.
  • In this report, we described a case of advanced neuroendocrine carcinoma of the stomach with the peripancreatic lymph node metastases which was treated with pancreaticoduodenectomy with extended lymphadenectomy.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor to be neuroendocrine carcinoma.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • The patient is well and has now been free of symptoms of recurrence and metastasis for 8 months.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


13. Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, Barakat RR: Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol; 2005 Feb;96(2):330-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.
  • OBJECTIVES: To analyze the feasibility of using percutaneous endoscopic gastrostomy (PEG) tube placement in ovarian cancer patients with malignant bowel obstruction and to analyze the outcome of these patients.
  • Abstracted data included patient demographics, procedure information, symptom resolution, diet tolerated, complications, further treatment, and survival.
  • RESULTS: Ninety-four patients with ovarian carcinoma requiring PEG tube placement for malignant bowel obstruction were identified.
  • The mean age at the time of PEG tube placement was 56 years.
  • Twenty-two of 77 patients who had a computed tomography (CT) scan prior to PEG tube placement had tumor encasing the stomach.
  • The mean hospital stay after the procedure was 6 days.
  • Chemotherapy after PEG tube placement was administered in 29 (31%) of the 94 patients, with resolution of obstruction and removal of the PEG tube in 4.
  • Selected patients (younger age and without liver metastasis) may benefit from chemotherapy after PEG tube placement.


14. Akagi I, Miyashita M, Hashimoto M, Makino H, Nomura T, Ohkawa K, Tsuchiya Y, Tajiri T: Cardiac tamponade due to metastasis from early gastric cancer. Clin J Gastroenterol; 2008 Oct;1(3):100-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade due to metastasis from early gastric cancer.
  • We report a case of cardiac tamponade caused by metastasis from early gastric cancer.
  • A 44-year-old woman was detected to have an abnormality of the stomach on barium meal during an annual medical checkup.
  • Computed tomography (CT) and ultrasonography (US) revealed no evidence of metastasis.
  • We performed distal gastrectomy with regional lymph node dissection.
  • Lymphatic invasion was detected only in the mucosal region beneath the tumor; however, lymph node metastasis was found in almost half of dissected lymph nodes.
  • Adjuvant chemotherapy was administered on an outpatient basis with 36 courses of mitomycinC infused (8 mg/day) once every 4 weeks.
  • However, 3 years after the surgery, the patient developed cardiac tamponade due to carcinomatous pericarditis.
  • We performed drainage of the malignant effusion and initiated treatment with S-1 and docetaxel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 1990;29(5):636-7 [2206579.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):909-13 [8352559.001]
  • [Cites] Angiology. 2004 Nov-Dec;55(6):691-5 [15547656.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1803-8 [16773074.001]
  • [Cites] Gastric Cancer. 2006;9(1):14-8 [16557431.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Oncology. 1992;49(6):489-91 [1465290.001]
  • [Cites] Drugs Exp Clin Res. 1985;11(2):123-5 [3915280.001]
  • [Cites] Gastroenterology. 1987 Sep;93(3):506-14 [3301516.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Jan;32(1):77-9 [15675587.001]
  • [Cites] Arch Pathol. 1964 Nov;78:467-73 [14200667.001]
  • [Cites] Kokyu To Junkan. 1983 May;31(5):569-73 [6635365.001]
  • [Cites] Circulation. 1960 Sep;22:474-83 [13711211.001]
  • [Cites] Oncology. 2005;68(2-3):130-7 [16006750.001]
  • [Cites] Support Care Cancer. 1997 Jan;5(1):64-6 [9010992.001]
  • [Cites] World J Gastroenterol. 2005 Nov 28;11(44):6899-904 [16437590.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] Cancer. 1972 Mar;29(3):799-808 [4501215.001]
  • [Cites] Pneumonol Alergol Pol. 1996;64 Suppl 2:180-6 [9181888.001]
  • [Cites] Gastric Cancer. 2007;10(2):135-9 [17577625.001]
  • [Cites] Biomed Pharmacother. 1984;38(7):332-7 [6596963.001]
  • [Cites] World J Surg Oncol. 2003 Oct 10;1(1):20 [14577834.001]
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):396-8 [10440198.001]
  • [Cites] Cancer Treat Rep. 1985 Nov;69(11):1327-8 [3867406.001]
  • [Cites] J Surg Oncol. 1982 Sep;21(1):18-22 [7109632.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):195-201 [3411785.001]
  • [Cites] Cancer Treat Rep. 1985 Jun;69(6):725-6 [3860295.001]
  • (PMID = 26193646.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Cardiac tamponade / Early gastric cancer / Metastasis / Pericardial effusion
  •  go-up   go-down


15. Kuroiwa M, Hiwatari M, Hirato J, Suzuki N, Tsuchida Y, Shimada A, Shitara T, Taki T, Hayashi Y: Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA. J Pediatr Surg; 2005 Nov;40(11):1798-801
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA.
  • A 12-year-old girl presented with a large abdominal tumor.
  • At surgery, a huge pedunculated extraluminal tumor was found arising from the greater curvature of the stomach and invading the surrounding structures, and there were also a submucosal tumor measuring 5 x 4 x 4 cm and multiple intramural nodules beside the main tumor.
  • A diagnosis of gastrointestinal stromal tumor (GIST) was made.
  • The huge size of the tumor (3.6 kg in weight and 36 x 25 x 25 cm in diameter), the invasion of the surrounding structures, and the increased mitotic figures indicated the GIST had malignant potential.
  • Sequence analysis of the polymerase chain reaction product of RNAs from the tumor cells revealed a novel platelet-derived growth factor receptor alpha (PDGFRA) mutation, which would exhibit biologic consequences similar to those of the c-kit mutation.
  • The patient underwent a 3-month course of imatinib mesylate as adjuvant chemotherapy because of the possible risk for tumor recurrence.
  • She is now doing well without any evidence of recurrence or metastasis 25 months after the surgery.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Benzamides. Chemotherapy, Adjuvant. Child. Female. Humans. Imatinib Mesylate. Mutation. Prognosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291174.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


16. Karnak I, Senocak ME, Ciftci AO, Cağlar M, Bingöl-Koloğlu M, Tanyel FC, Büyükpamukçu N: Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg; 2001 Jun;36(6):908-12
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: diagnosis and treatment.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm.
  • Furthermore, malignant degeneration or transformation to lymphoma in the recurrent or residual IMT have directed attention to this interesting entity.
  • Herein, the authors present their experience with IMT with special emphasis on diagnosis and treatment.
  • Tumor sizes ranged from 3 x 2 x 2 cm to 15 x 15 x 13 cm.
  • Infiltrated organs (esophagogastric junction, a segment of jejunum, and spleen, stomach wall, and renal capsule) were resected in 3 cases.
  • Total surgical excision of IMT was considered adequate for treatment in 6 cases.
  • One patient with aggressive IMT required further treatments such as immunomodulation and chemotherapy and died of neutropenic sepsis.
  • CONCLUSIONS: IMT is a benign neoplasm rarely presented with malignant features such as local invasiveness, recurrence, distant metastasis, or malignant transformation.
  • Complete surgical resection and close follow-up are all necessary for appropriate treatment to avoid recurrences as well as unnecessary and potentially harmful therapy.
  • [MeSH-minor] Child. Female. Humans. Male. Recurrence. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11381424.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


17. Farhat MH, Moumneh G, Jalloul R, El Hout Y: Secondary adenocarcinoma of the urinary bladder from a primary gastric cancer. J Med Liban; 2007 Jul-Sep;55(3):162-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary bladder tumor is a frequent urological malignancy, whereas the incidence of secondary bladder tumor from a distant organ is quite rare.
  • Secondary bladder neoplasms represent no more than 3% of all malignant bladder tumors in surgical specimens, of which distant metastases from stomach account for about 4%.
  • We present a patient with primary adenocarcinoma of the stomach, who underwent total gastrectomy and received adjuvant chemotherapy, and was diagnosed with metastasis to the urinary bladder 15 months later.
  • We review the epidemiology of secondary adenocarcinoma of the bladder, mechanisms of metastasis, associated common primaries with focus on gastric malignancies, radiological findings, and role of immunohistochemical staining.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Med Liban. 2008 Jan-Mar;56(1):48 [19534093.001]
  • (PMID = 17966739.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Lebanon
  • [Number-of-references] 16
  •  go-up   go-down


18. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M: Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer; 2006;9(1):44-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to its regulation by oncogenes or tumor suppressor genes such as HER2, p53, VHL, and PTEN, overexpression of HIF-1alpha is induced by hypoxia.
  • Increased HIF-1alpha expression is associated with malignant potential, and with patient prognosis and response to chemoradiotherapy in some cancer types.
  • Furthermore, we analyzed the impact of HIF-1alpha, VEGF, and p53 protein expression on resistance to chemotherapy in advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Cell Differentiation. Humans. Immunoenzyme Techniques. Lymph Nodes. Lymphatic Metastasis. Neoplasm Invasiveness / pathology. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2004 May;5(5):405-6 [15144945.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 May;14(5):831-8 [3360652.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):215-23 [11804750.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Trends Mol Med. 2001 Aug;7(8):345-50 [11516994.001]
  • [Cites] J Biomed Sci. 2005;12(1):229-41 [15864753.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5215-22 [11431362.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1541-5 [10749120.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Genes Dev. 2000 Feb 15;14 (4):391-6 [10691731.001]
  • [Cites] Nat Med. 2000 Dec;6(12 ):1335-40 [11100117.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):176-82 [15771621.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):200-8 [15245814.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):419-24 [14984367.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):31-4 [11454426.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):946-56 [15199114.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3995-4004 [11359907.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • (PMID = 16557436.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


19. Li J, Liu P, Wang H, Yu J, Xie P, Liu X: [Clinical analysis of 31 patients with gastric stromal tumors]. Zhonghua Nei Ke Za Zhi; 2002 Nov;41(11):742-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of gastric stromal tumors.
  • Diagnosis of this condition is sometimes difficult and treatment is often delayed because patients usually present with nonspecific abdominal symptoms.
  • Most of them were malignant.
  • Gastroscopy, ultrasound gastroscopy, computed tomography, B type ultrasound and upper gastrointestinal X-ray series are helpful to diagnosis.
  • The operative treatment is thought of the first choice.
  • Effect of the chemotherapy isn't satisfied.
  • There is no standard chemotherapy for gastric stromal tumors.
  • CONCLUSIONS: Gastric stromal tumor is a kind of separated submucosal tumor which is different from leiomyoma, leiomyosarcoma and neurogenic tumors.
  • Early diagnosis and rational treatment are the keys to improve the prognosis.
  • [MeSH-major] Stomach Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485519.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Lordick F, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G: [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr; 2010 Aug;135(34-35):1671-82; quiz 1683-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of gastric cancer].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms.
  • From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death.
  • A sophisticated staging should include high-resolution computed tomography of the thorax, abdomen and pelvis and video-documented endoscopy and endoscopic ultrasound.
  • In the stages II and III perioperative chemotherapy has been established as a standard of care and should be applied.
  • In the metastatic setting, treatment goals are palliative.
  • Chemotherapy can prolong survival, improve symptoms and can help to maintain a better quality of life.
  • Combination chemotherapy including a platinum compound and a fluoropyrimidine regarded as standard.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Endoscopy, Digestive System. Epirubicin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Gastric Mucosa / pathology. Humans. Laparoscopy. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20721843.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  • [Number-of-references] 40
  •  go-up   go-down


21. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


22. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


23. Liang J, Bai F, Luo G, Wang J, Liu J, Ge F, Pan Y, Yao L, Du R, Li X, Fan R, Zhang H, Guo X, Wu K, Fan D: Hypoxia induced overexpression of PrP(C) in gastric cancer cell lines. Cancer Biol Ther; 2007 May;6(5):769-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular prion protein (PrP(C)), a copper-binding glycosyl-phosphatidylinositol (GPI)-anchored membrane protein that is expressed predominantly in neurons can be induced in ischemia/hypoxic brain tissues.
  • It was also found to be overexpressed and conferred multidrug resistance, promoting cancer metastasis and inhibiting apoptosis in gastric cancer in our lab.
  • In solid tumors, hypoxia can promote malignant progression and confer resistance to chemotherapy by altering gene expression.
  • PrP(C) was detected to be upregulated in several cancer cell lines at both mRNA and protein level, and then found to be induced by hypoxia in a time-dependent manner.
  • After hypoxia treatment, gastric cancer MKN28 cells transfected with luciferase reporter constructs of the human PrP(C) promoter, which contained HSE, expressed higher luciferase activities (4.3-fold) than those cells transfected with the constructs containing no HSE.
  • siRNA knockdown of PrP(C) could make the cells more sensitive to hypoxia induced drug sensitivity.
  • Downregulation of PrP(C) makes gastric cancer cells more sensitive to hypoxia induced drug sensitivity.
  • [MeSH-major] Anoxia / metabolism. PrPC Proteins / metabolism. Response Elements. Stomach Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Drug Screening Assays, Antitumor. Extracellular Signal-Regulated MAP Kinases / metabolism. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. MAP Kinase Signaling System. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Transcriptional Activation. Tumor Cells, Cultured. Up-Regulation


24. Nabeshima S, Kishihara Y, Nabeshima A, Yamaga S, Kinjo M, Kashiwagi S, Hayashi J: Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis. Fukuoka Igaku Zasshi; 2003 Jul;94(7):235-40
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological findings from bone marrow showed metastasis of adenocarcinoma with signet-ring cells, although the primary site was unknown.
  • To reduce tumor cells in number and improve DIC, 11 cycles of 5-Fluorouracil and leucovorin therapy were done, and the patient survived for 12 months.
  • Autopsy showed a 0.8 cm diameter, poorly differentiated adenocarcinoma with the signet-ring cell type in the lamina propria of the Vater's ampulla.
  • Many metastatic foci and micro tumor emboli were found in the lung and in bone marrow.
  • The sections of the stomach, the gallbladder, urinary bladder, prostate, and thyroid gland showed no malignant cells.
  • This is a rare case of an ampullary tumor of poorly differentiated adenocarcinoma with the signet-ring cell type, without jaundice but with multiple metastasis.
  • 5-Fluorouracil and leucovorin were effective for increasing survival time and improving quality of life.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / complications. Disseminated Intravascular Coagulation / drug therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Jaundice. Leucovorin / administration & dosage. Male. Middle Aged. Neoplastic Cells, Circulating / pathology. Quality of Life

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14509231.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement